Publication date: Jul 14, 2025
Idiopathic pulmonary fibrosis (IPF) is a life-threatening interstitial lung disease and is one of the complications observed in individuals following COVID-19 infection. Although inhalable nanomedicines hold promise, nebulization-induced shear stress, dense airway mucus barrier, and inefficient in vivo clearance substantially compromise nanomedicine delivery efficiency and biosafety, thereby limiting their therapeutic efficacies. Herein, an inhalable microenvironment-responsive hybrid nanomedicine (PFD@FPNs-CAT) encapsulated with pirfenidone (PFD) and modified with catalase (CAT) is developed, which is able to overcome the supramolecular interactions owing to the small particle size, electronegativity, and PEGylated surface, thus enhancing the accumulation of PFD@FPNs-CAT in the lesions. Moreover, the surface-anchored CAT is demonstrated to relieve hypoxia, thus reversing the immunosuppressive microenvironment and further enhancing the therapeutic efficacy against IPF. Notably, due to the relatively low quantity of silica doping, PFD@FPNs-CAT demonstrates high stability and excellent biocompatibility. This inhalable mucus-penetrating nanomedicine remarkably inhibits the progression of IPF, illuminating the bright prospects for IPF therapy.
| Concepts | Keywords |
|---|---|
| Cat | hybrid nanoparticle |
| Immunosuppressive | idiopathic pulmonary fibrosis |
| Nanomedicines | inhalable nanomedicine |
| Pulmonary | mucus penetration |
| Vivo | pulmonary drug delivery |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Idiopathic Pulmonary Fibrosis |
| disease | MESH | interstitial lung disease |
| disease | MESH | complications |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| drug | DRUGBANK | Bentiromide |
| drug | DRUGBANK | Pirfenidone |
| disease | MESH | hypoxia |
| drug | DRUGBANK | Silicon dioxide |